Calmark receives order from Turkey regarding Neo-products.

Calmark Sweden AB (publ) announces today that the Company has received an order from the distributor in Turkey, Savas Medical covering the Calmark Neo platform. The economic value of today's order is of minor importance, but it is important from a launch perspective

‘The registration of Neo-Bilirubin in Turkey was completed last week. The fact that our distributor places an order immediately is positive and shows that they, just like us, have been waiting to get started with the launch.’  says Magdalena Tharaldsen, Director International Business Development for Calmark.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-09-2023 18:53 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.